-col-
avelumab
figitumumab
adecatumumab
tenatumomab
dacetuzumab
tigatuzumab
conatumumab
naptumomab estafenatox
nofetumomab
-les-
inotuzumab
acrixolimab
-got-
duligotuzumab
pamrevlumab
sibrotuzumab
inotuzumab ozogamicin
panitumumab
ramucirumab
cixutumumab
onartuzumab
tisotumab
-pro-
patritumab
labetuzumab
mapatumumab
oleclumab
lintuzumab
olendalizumab
dalotuzumab
votumumab
matuzumab
lexatumumab
-tum-
carlumab
-mel-
cantuzumab
agonistic monoclonal antibody
samalizumab
drozitumab
tremelimumab
satumomab
lucatumumab
etaracizumab
teprotumumab
nacolomab tafenatox
endotrophin
cemiplimab
catumaxomab
alacizumab
oportuzumab monatox
ertumaxomab
muromonab
iratumumab
volociximab
atezolizumab
epichaperome
milatuzumab
nimotuzumab
apolizumab
colitis
amivantamab
durvalumab
cergutuzumab
olaratumab
abagovomab
pidilizumab
brolucizumab
ravulizumab
gevokizumab
tislelizumab
siltuximab
relatlimab
antimonoclonal
pertuzumab
colonocyte
abituzumab
robatumumab
folliculin
-toxa-
altumomab
zalutumumab
colosphere
oncotropic
carcinosarcoma
inflammatory bowel disease
arcitumomab
sigmoideum
ensituximab
besilesomab
antinucleosome
hexastatin
detumomab
sigmoid flexure
oncoimmunology
malignin
rectosigmoiditis
taplitumomab